Uniform Data Set version 4
UDSv4 - Template

United States

Reference ID

USDv4

Producer(s)

National Alzheimer’s Coordinating Center (NACC) and the NIA-funded ADRC network

Collections

Clinical Trial

Metadata

DDI/XML JSON

Created on

Jul 02, 2026

Last modified

Jul 07, 2026

Page views

11408

Variable Groups

Variable group: A4a ADRD Specific Treatments

Variables 137

a4a_adrd_specific_treatment
s_complete

adverseoth

IVP Q3a3./FVP Q3b3. Adverse events to modify ADRD biomarkers - Other

adverseotx

IVP Q3a3a./FVP Q3b3a. Adverse events to modify ADRD biomarkers - Other, specify

advevent

3. Has the participant ever experienced amyloid related imaging abnormalities-edema (ARIA-E), amyloid related imaging abnormalities-hemorrhage (ARIA-H), or other major adverse events associated with treatments expected to modify ADRD biomarkers?

ariae

IVP Q3a1./FVP Q3b1. Amyloid related imaging abnormalities-edema (ARIA-E)

ariah

IVP Q3a2./FVP Q3b2. Amyloid related imaging abnormalities-hemorrhage (ARIA-H)

caretrial1

2a5. How was the treatment provided? (1)

caretrial2

2b5. How was the treatment provided? (2)

caretrial3

2c5. How was the treatment provided? (3)

caretrial4

2d5. How was the treatment provided? (4)

caretrial5

2e5. How was the treatment provided? (5)

caretrial6

2f5. How was the treatment provided? (6)

caretrial7

2g5. How was the treatment provided? (7)

caretrial8

2h5. How was the treatment provided? (8)

endmo1

2a4a. End date (month) (1)

endmo2

2b4a. End date (month) (2)

endmo3

2c4a. End date (month) (3)

endmo4

2d4a. End date (month) (4)

endmo5

2e4a. End date (month) (5)

endmo6

2f4a. End date (month) (6)

endmo7

2g4a. End date (month) (7)

endmo8

2h4a. End date (month) (8)

endyear1

2a4b. End date (year) (1)

endyear2

2b4b. End date (year) (2)

endyear3

2c4b. End date (year) (3)

endyear4

2d4b. End date (year) (4)

endyear5

2e4b. End date (year) (5)

endyear6

2f4b. End date (year) (6)

endyear7

2g4b. End date (year) (7)

endyear8

2h4b. End date (year) (8)

frmdatea4a

0a. A4a AD-Specific Drug Treatment - Form date

initialsa4a

0b. A4a AD-Specific Drug Treatment - Examiner's initials

langa4a

0c. A4a AD-Specific Drug Treatment - Language

loc_adevent

IVP Q3a./FVP Q3b. What major adverse events associated with treatments expected to modify ADRD biomarkers did they experience? (select all that apply)

loc_tgt1

2a1a-2a1e Primary Drug Target

loc_tgt2

2b1a-2b1e Primary Drug Target

loc_tgt3

2c1a-2c1e Primary Drug Target (3)

loc_tgt4

2d1a-2d1e Primary Drug Target

loc_tgt5

2e1a-2e1e Primary Drug Target

loc_tgt6

2f1a-2f1e Primary Drug Target

loc_tgt7

2g1a-2g1e Primary Drug Target

loc_tgt8

2h1a-2h1e Primary Drug Target

loc_trt_num

How many treatments/trials?

modea4a

0d. A4a AD-Specific Drug Treatment - In-person or remote?

nctnum1

2a2b. Specific treatment and/or trial - NCT identifier (1)

nctnum2

2b2b. Specific treatment and/or trial - NCT identifier (2)

nctnum3

2c2b. Specific treatment and/or trial - NCT identifier (3)

nctnum4

2d2b. Specific treatment and/or trial - NCT identifier (4)

nctnum5

2e2b. Specific treatment and/or trial - NCT identifier (5)

nctnum6

2f2b. Specific treatment and/or trial - NCT identifier (6)

nctnum7

2g2b. Specific treatment and/or trial - NCT identifier (7)

nctnum8

2h2b. Specific treatment and/or trial - NCT identifier (8)

newadevent

3a. Since the last UDS visit, is new information available concerning the participant's experience of amyloid related imaging abnormalities-edema (ARIA-E), amyloid related imaging abnormalities-hemorrhage (ARIA-H), or other major adverse events associated

newtreat

1a. Since the last UDS visit, is new information available concerning any of the participant's prescribed treatments or clinical trial(s) of a treatment expected to modify ADRD biomarkers?

rmmodea4a

0d1a. What modality was used to collect this remote 'A4a AD-Specific Drug Treatment' form?

rmreasa4a

0d1. If 'A4a AD-Specific Drug Treatment' form was completed remotely, specify reason

startmo1

2a3a. Start date (month) (1)

startmo2

2b3a. Start date (month) (2)

startmo3

2c3a. Start date (month) (3)

startmo4

2d3a. Start date (month) (4)

startmo5

2e3a. Start date (month) (5)

startmo6

2f3a. Start date (month) (6)

startmo7

2g3a. Start date (month) (7)

startmo8

2h3a. Start date (month) (8)

startyear1

2a3b. Start date (year) (1)

startyear2

2b3b. Start date (year) (2)

startyear3

2c3b. Start date (year) (3)

startyear4

2d3b. Start date (year) (4)

startyear5

2e3b. Start date (year) (5)

startyear6

2f3b. Start date (year) (6)

startyear7

2g3b. Start date (year) (7)

startyear8

2h3b. Start date (year) (8)

targetab1

2a1a. Primary Drug Target - Amyloid Beta (1)

targetab2

2b1a. Primary Drug Target - Amyloid Beta (2)

targetab3

2c1a. Primary Drug Target - Amyloid Beta (3)

targetab4

2d1a. Primary Drug Target - Amyloid Beta (4)

targetab5

2e1a. Primary Drug Target - Amyloid Beta (5)

targetab6

2f1a. Primary Drug Target - Amyloid Beta (6)

targetab7

2g1a. Primary Drug Target - Amyloid Beta (7)

targetab8

2h1a. Primary Drug Target - Amyloid Beta (8)

targetinf1

2a1c. Primary Drug Target - Inflammation (1)

targetinf2

2b1c. Primary Drug Target - Inflammation (2)

targetinf3

2c1c. Primary Drug Target - Inflammation (3)

targetinf4

2d1c. Primary Drug Target - Inflammation (4)

targetinf5

2e1c. Primary Drug Target - Inflammation (5)

targetinf6

2f1c. Primary Drug Target - Inflammation (6)

targetinf7

2g1c. Primary Drug Target - Inflammation (7)

targetinf8

2h1c. Primary Drug Target - Inflammation (8)

targetoth1

2a1e. Primary Drug Target - Other target(s) (1)

targetoth2

2b1e. Primary Drug Target - Other target(s) (2)

targetoth3

2c1e. Primary Drug Target - Other target(s) (3)

targetoth4

2d1e. Primary Drug Target - Other target(s) (4)

targetoth5

2e1e. Primary Drug Target - Other target(s) (5)

targetoth6

2f1e. Primary Drug Target - Other target(s) (6)

targetoth7

2g1e. Primary Drug Target - Other target(s) (7)

targetoth8

2h1e. Primary Drug Target - Other target(s) (8)

targetotx1

2a1e1. Primary Drug Target - Other target(s), specify (1)

targetotx2

2b1e1. Primary Drug Target - Other target(s), specify (2)

targetotx3

2c1e1. Primary Drug Target - Other target(s), specify (3)

targetotx4

2d1e1. Primary Drug Target - Other target(s), specify (4)

targetotx5

2e1e1. Primary Drug Target - Other target(s), specify (5)

targetotx6

2f1e1. Primary Drug Target - Other target(s), specify (6)

targetotx7

2g1e1. Primary Drug Target - Other target(s), specify (7)

targetotx8

2h1e1. Primary Drug Target - Other target(s), specify (8)

targetsyn1

2a1d. Primary Drug Target - Synaptic plasticity / neuroprotection (1)

targetsyn2

2b1d. Primary Drug Target - Synaptic plasticity/neuroprotection (2)

targetsyn3

2c1d. Primary Drug Target - Synaptic plasticity/neuroprotection (3)

targetsyn4

2d1d. Primary Drug Target - Synaptic plasticity/neuroprotection (4)

targetsyn5

2e1d. Primary Drug Target - Synaptic plasticity/neuroprotection (5)

targetsyn6

2f1d. Primary Drug Target - Synaptic plasticity/neuroprotection (6)

targetsyn7

2g1d. Primary Drug Target - Synaptic plasticity/neuroprotection (7)

targetsyn8

2h1d. Primary Drug Target - Synaptic plasticity/neuroprotection (8)

targettau1

2a1b. Primary Drug Target - Tau (1)

targettau2

2b1b. Primary Drug Target - Tau (2)

targettau3

2c1b. Primary Drug Target - Tau (3)

targettau4

2d1b. Primary Drug Target - Tau (4)

targettau5

2e1b. Primary Drug Target - Tau (5)

targettau6

2f1b. Primary Drug Target - Tau (6)

targettau7

2g1b. Primary Drug Target - Tau (7)

targettau8

2h1b. Primary Drug Target - Tau (8)

trialgrp1

2a6. If clinical trial, in which group was the participant? (1)

trialgrp2

2b6. If clinical trial, in which group was the participant? (2)

trialgrp3

2c6. If clinical trial, in which group was the participant? (3)

trialgrp4

2d6. If clinical trial, in which group was the participant? (4)

trialgrp5

2e6. If clinical trial, in which group was the participant? (5)

trialgrp6

2f6. If clinical trial, in which group was the participant? (6)

trialgrp7

2g6. If clinical trial, in which group was the participant? (7)

trialgrp8

2h6. If clinical trial, in which group was the participant? (8)

trtbiomark

1. Has the participant ever been prescribed a treatment or been enrolled in a clinical trial of a treatment expected to modify ADRD biomarkers?

trttrial1

2a2. Specific treatment and/or trial (1)

trttrial2

2b2. Specific treatment and/or trial (2)

trttrial3

2c2. Specific treatment and/or trial (3)

trttrial4

2d2. Specific treatment and/or trial (4)

trttrial5

2e2. Specific treatment and/or trial (5)

trttrial6

2f2. Specific treatment and/or trial (6)

trttrial7

2g2. Specific treatment and/or trial (7)

trttrial8

2h2. Specific treatment and/or trial (8)

Back to Catalog